The following represents disclosure information provided by authors of this abstract. The Breast Cancer Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Effect of denosumab versus zoledronic acid on health-related quality of life in patients with metastatic breast cancer.
L. Fallowfield
Consultant or Advisory Role - Amgen
Honoraria - Amgen
D. Patrick
Consultant or Advisory Role - Amgen
J. Body
Consultant or Advisory Role - Amgen; Novartis
Honoraria - Amgen; Novartis
Research Funding - Amgen
A. Lipton
Consultant or Advisory Role - Amgen; Novartis
Honoraria - Amgen; Novartis
Research Funding - Novartis
Expert Testimony - Novartis
K. S. Tonkin
No relevant relationships to disclose
Y. Qian
Employment or Leadership Position - Amgen
Consultant or Advisory Role - Amgen
Stock Ownership - Amgen
Honoraria - Amgen
Q. Jiang
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
A. H. Braun
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Research Funding - Amgen
R. D. Dansey
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Research Funding - Amgen
K. Chung
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Research Funding - Amgen